Mylan accused by U.S. of overcharging on Medicaid for years
While Mylan says its discounts were consistent with federal guidance, the government says the company owed bigger discounts on EpiPen.
By Robert Langreth|October 07, 2016 at 08:05 AM
Thank you for sharing!
Your article was successfully shared with the contacts you provided.
Mylan NV has been overcharging the U.S. for years on its EpiPen allergy shot, a government agency said, as two lawmakers said the company was “bilking” taxpayers and may have made billions by misclassifying the drug under complex Medicaid pricing rules.
It’s no secret that health benefits have struggled to keep up with workforce expectations during the Great Resignation. Remaining competitive means employers must streamline their health benefits, put employees first and deliver on brand values. Download this guide to help your clients gain an edge in 2022 with their health benefits.
Amid mass resignations and record-high job openings, employees are now firmly in the driver’s seat when it comes to where and how they work. So, how are you going to stand out in this highly competitive market? This guide outlines a forward-thinking health benefits strategy that will ensure your company remains competitive in 2022 and beyond.
Millennials and Gen Z value tobacco and nicotine cessation more than ever before, but quit programs must adapt to their evolving needs. New research indicates successful quit programs have three key facets. Download this interactive ebook to learn how to set your company apart with an effective quit services benefit.